Conditions: Adenocarcinoma of the Gastroesophageal Junction; Metastatic Malignant Neoplasm in the Lymph Nodes; Recurrent Gastric Carcinoma; Stage IV Gastric Cancer
Interventions: Other: Laboratory Biomarker Analysis; Drug: Olaparib; Other: Quality-of-Life Assessment; Biological: Ramucirumab
Sponsor: National Cancer Institute (NCI)
Not yet recruiting - verified December 2016
Next Steps in Immuno-Oncology: Enhancing Antitumor Effects - Is dual immune checkpoint blockade synergistic and safe? Find the latest research here. *Annals of Oncology* from Uncategorized via xlomafota13 on Inoreade...